Literature DB >> 21523468

Targeting the target of rapamycin (TOR): looking to mother nature.

Eric K Rowinsky.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21523468     DOI： 10.1007/s11523-011-0180-y

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  32 in total

Review 1.  High-throughput screening of natural products for cancer therapy.

Authors:  Alan L Harvey; Ian A Cree
Journal:  Planta Med       Date:  2010-07-15       Impact factor: 3.352

Review 2.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances.

Authors:  Sheng-Yong Yang
Journal:  Drug Discov Today       Date:  2010-04-01       Impact factor: 7.851

Review 3.  Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.

Authors:  Hakan Cam; Peter J Houghton
Journal:  Target Oncol       Date:  2011-04-16       Impact factor: 4.493

Review 4.  Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Authors:  Zelton Dave Sharp; Arlan Richardson
Journal:  Target Oncol       Date:  2011-03-11       Impact factor: 4.493

Review 5.  Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Authors:  Sumanta Kumar Pal; Robert A Figlin
Journal:  Target Oncol       Date:  2011-04-12       Impact factor: 4.493

6.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

7.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.

Authors:  B P Zhou; M C Hu; S A Miller; Z Yu; W Xia; S Y Lin; M C Hung
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

8.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

9.  The LKB1 tumor suppressor negatively regulates mTOR signaling.

Authors:  Reuben J Shaw; Nabeel Bardeesy; Brendan D Manning; Lyle Lopez; Monica Kosmatka; Ronald A DePinho; Lewis C Cantley
Journal:  Cancer Cell       Date:  2004-07       Impact factor: 31.743

Review 10.  Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Authors:  Yesid Alvarado; Monica M Mita; Sushma Vemulapalli; Devalingam Mahalingam; Alain C Mita
Journal:  Target Oncol       Date:  2011-05-04       Impact factor: 4.864
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.